Defining the minimal important change and meaningful change value of the disease activity index for psoriatic arthritis: a Chinese longitudinal study
CONCLUSION: MIC, offering physicians an additional means to contextualize the patient's perception of disease activity during treatment, and a change of 10.5 is likely to be regarded as a clinically meaningful change, enhancing the utility of DAPSA in PsA clinical trials.PMID:38490673 | DOI:10.3899/jrheum.2023-1085 (Source: J Rheumatol)
Source: J Rheumatol - March 15, 2024 Category: Rheumatology Authors: Yijie Liu Minjia Tan Kun Hu SiChun Deng Lu Jian Junchen Chen Mi Zhang Yehong Kuang Source Type: research
Defining the minimal important change and meaningful change value of the disease activity index for psoriatic arthritis: a Chinese longitudinal study
CONCLUSION: MIC, offering physicians an additional means to contextualize the patient's perception of disease activity during treatment, and a change of 10.5 is likely to be regarded as a clinically meaningful change, enhancing the utility of DAPSA in PsA clinical trials.PMID:38490673 | DOI:10.3899/jrheum.2023-1085 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - March 15, 2024 Category: Rheumatology Authors: Yijie Liu Minjia Tan Kun Hu SiChun Deng Lu Jian Junchen Chen Mi Zhang Yehong Kuang Source Type: research
Defining the minimal important change and meaningful change value of the disease activity index for psoriatic arthritis: a Chinese longitudinal study
CONCLUSION: MIC, offering physicians an additional means to contextualize the patient's perception of disease activity during treatment, and a change of 10.5 is likely to be regarded as a clinically meaningful change, enhancing the utility of DAPSA in PsA clinical trials.PMID:38490673 | DOI:10.3899/jrheum.2023-1085 (Source: J Rheumatol)
Source: J Rheumatol - March 15, 2024 Category: Rheumatology Authors: Yijie Liu Minjia Tan Kun Hu SiChun Deng Lu Jian Junchen Chen Mi Zhang Yehong Kuang Source Type: research
Defining the minimal important change and meaningful change value of the disease activity index for psoriatic arthritis: a Chinese longitudinal study
CONCLUSION: MIC, offering physicians an additional means to contextualize the patient's perception of disease activity during treatment, and a change of 10.5 is likely to be regarded as a clinically meaningful change, enhancing the utility of DAPSA in PsA clinical trials.PMID:38490673 | DOI:10.3899/jrheum.2023-1085 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - March 15, 2024 Category: Rheumatology Authors: Yijie Liu Minjia Tan Kun Hu SiChun Deng Lu Jian Junchen Chen Mi Zhang Yehong Kuang Source Type: research
Defining the minimal important change and meaningful change value of the disease activity index for psoriatic arthritis: a Chinese longitudinal study
CONCLUSION: MIC, offering physicians an additional means to contextualize the patient's perception of disease activity during treatment, and a change of 10.5 is likely to be regarded as a clinically meaningful change, enhancing the utility of DAPSA in PsA clinical trials.PMID:38490673 | DOI:10.3899/jrheum.2023-1085 (Source: J Rheumatol)
Source: J Rheumatol - March 15, 2024 Category: Rheumatology Authors: Yijie Liu Minjia Tan Kun Hu SiChun Deng Lu Jian Junchen Chen Mi Zhang Yehong Kuang Source Type: research
Successful use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - March 15, 2024 Category: Dermatology Authors: M. Grace Hren, Sophie Guenin, Saakshi Khattri Source Type: research
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
ConclusionsAccording to MAICs, bimekizumab demonstrated greater or comparable efficacy on ACR50/70 and MDA outcomes than guselkumab in patients with PsA who were bDMARD-na ïve and TNFi-IR at week 48/52. Bimekizumab had a more favorable likelihood than guselkumab in achieving more stringent treatment outcomes.Trial RegistrationsNCT03895203, NCT03896581, NCT04009499, NCT03158285, NCT03796858. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 15, 2024 Category: Rheumatology Source Type: research
Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease
To the Editor: Patients with severe atopic dermatitis (AD), psoriasis (PSO), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD) may present as a therapeutic challenge to clinicians. Rarely, patients may present with 2 of these systemic inflammatory diseases. For these patients, dual biologic therapy may offer a solution. Although dual biologic therapy is infrequently described, published reports describe promising results.1,2 Hesitation to prescribe dual therapy may exist due to concern of paradoxical upregulation of a separate axis after inhibition of intended axis, high costs, risk of infection, and lack ...
Source: Journal of the American Academy of Dermatology - March 15, 2024 Category: Dermatology Authors: Mary Grace Hren, Sophie Guenin, Saakshi Khattri Tags: Research letter Source Type: research
Different biologics for biological-na ïve patients with psoriatic arthritis: a systematic review and network meta-analysis
Conclusion: In 2023, considering both efficacy and safety, IL-17Ai may be the better treatment option for biological-naïve patients with PsA requiring biological therapy. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Source Type: research
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
The Advances in Targeted Therapies meets annually, convening experts in the field of rheumatology to both provide scientific updates and identify existing scientific gaps within the field. To review the major unmet scientific needs in rheumatology. The 23rd annual Advances in Targeted Therapies meeting convened with more than 100 international basic scientists and clinical researchers in rheumatology, immunology, infectious diseases, epidemiology, molecular biology and other specialties relating to all aspects of immune-mediated inflammatory diseases. We held breakout sessions in five rheumatological disease-specific group...
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Winthrop, K. L., Mease, P., Kerschbaumer, A., Voll, R. E., Breedveld, F. C., Smolen, J. S., Gottenberg, J.-E., Baraliakos, X., Kiener, H. P., Aletaha, D., Isaacs, J. D., Buch, M. H., Crow, M. K., Kay, J., Crofford, L., van Vollenhoven, R. F., Ospelt, C., Tags: ARD Viewpoint Source Type: research
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study
Conclusions
Mortality risk in PsA in Sweden was about 10% higher than in the general population, driven by excess comorbidity and with increased risks mainly in women and patients with longer disease duration. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Exarchou, S., Di Giuseppe, D., Klingberg, E., Sigurdardottir, V., Wedren, S., Lindström, U., Turesson, C., Jacobsson, L. T. H., Askling, J., Wallman, J. K. Tags: Editor's choice, ARD, Psoriatic arthritis Source Type: research
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis
ConclusionIn biologic-na ïve patients with active PsA treated with guselkumab, achieving ER or DR was associated with durable improvements in selected PROs, including those of high importance to patients.Trial registrationClinicalTrials.gov (https://clinicaltrials.gov) NCT03158285; Registered: May 16, 2017.Key Points•At week 100, 65% and 76% of guselkumab-treated patients achieved enthesitis and dactylitis resolution (ER/DR).•Achieving ER was associated with achieving DR and vice versa through the end of study.•Achieving ER or DR was associated with durable and meaningful improvements in selected patient-reported ou...
Source: Clinical Rheumatology - March 12, 2024 Category: Rheumatology Source Type: research
Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia
ConclusionsIn this Australian real-world dataset, tofacitinib was more frequently used in later lines and among a slightly higher proportion of female patients than IL-17Ai or TNFi. Overall, treatment persistence was similar for tofacitinib, IL-17Ai and TNFi, but tofacitinib exhibited longer persistence than TNFi in a matched population.Key Points•This is the first, large real-world study from Australia investigating the demographics, treatment patterns and comparative treatment persistence of patients with psoriatic arthritis (PsA) treated with tofacitinib and biologic disease-modifying drugs (bDMARDs).•The study sugg...
Source: Clinical Rheumatology - March 9, 2024 Category: Rheumatology Source Type: research
Treatment of Nail Psoriasis
This article reviews available intralesional, topical, and systemic treatment options for nail psoriasis, and discusses efficacy and safety of studied agents. Also reviewed are consensus treatment guideline recommendations. An updated algorithm to aid physicians in selection of specific treatment options is provided. (Source: Dermatologic Clinics)
Source: Dermatologic Clinics - March 9, 2024 Category: Dermatology Authors: Jonathan K. Hwang, Shari R. Lipner Source Type: research
The subanalysis of Rheuma-VOR demonstrates a considerable need for rheumatological care
DISCUSSION: The available data show that a rheumatological presentation was indicated for the majority of patients. Owing to the increasing deficits in medical care a prior selection of the patients is crucial to make optimal use of restricted rheumatological capacities.PMID:38456907 | DOI:10.1007/s00393-024-01490-2 (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - March 8, 2024 Category: Rheumatology Authors: Stefanie Hirsch K Hoeper D Meyer-Olson A Schwarting K Gente M Dreher J Hoeper T Witte T Thiele Source Type: research
